PMID- 36630122
OWN - NLM
STAT- Publisher
LR  - 20240216
IS  - 1744-4160 (Electronic)
IS  - 1381-3455 (Linking)
DP  - 2023 Jan 11
TI  - The predicted mechanisms and evidence of probiotics on type 2 diabetes mellitus 
      (T2DM).
PG  - 1-16
LID - 10.1080/13813455.2022.2163260 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a serious endocrine and metabolic disease that 
      is highly prevalent and causes high mortality and morbidity rates worldwide. This 
      review aims to focus on the potential of probiotics in the management of T2DM and 
      its complications and to summarise the various mechanisms of action of probiotics 
      with respect to T2DM. In this review, experimental studies conducted between 2016 
      and 2022 were explored. The possible mechanisms of action are based on their 
      ability to modulate the gut microbiota, boost the production of short-chain fatty 
      acids (SCFAs) and glucagon-like peptides, inhibit alpha-glucosidase, elevate sirtuin 
      1 (SIRT1) levels while reducing fetuin-A levels, and regulate the level of 
      inflammatory cytokines. This review recommends carrying out further studies, 
      especially human trials, to provide robust evidence-based knowledge on the use of 
      probiotics for the treatment of T2DM.IMPACT STATEMENTT2DM is prevalent worldwide 
      causing high rates of morbidity and mortality.Gut microbiota play a significant 
      role in the pathogenesis of T2DM.Probiotics can be used as possible therapeutic 
      tools for the management of T2DM.The possible mechanisms of action of probiotics 
      include modulation of the gut microbiota, production of SCFAs and glucagon-like 
      peptides, inhibition of alpha-glucosidase, raising SIRT1, reducing fetuin-A levels, 
      and regulating the level of inflammatory cytokines.
FAU - Bajinka, Ousman
AU  - Bajinka O
AD  - Department of Medical Microbiology, Central South University, Changsha, China.
AD  - China-Africa Research Center of Infectious Diseases, School of Basic Medical 
      Sciences, Central South University, Changsha, China.
FAU - Sylvain Dovi, Kodzovi
AU  - Sylvain Dovi K
AD  - Department of Occupational and Environmental Health, Xiangya School of Public 
      Health, Central South University, Changsha, P. R. China.
FAU - Simbilyabo, Lucette
AU  - Simbilyabo L
AD  - Department of Neurosurgery, Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Conteh, Ishmail
AU  - Conteh I
AD  - Department of Epidemiology and Health Statistics, Xiangya School of public health 
      central South University, Changsha, P. R. China.
FAU - Tan, Yurong
AU  - Tan Y
AD  - Department of Medical Microbiology, Central South University, Changsha, China.
AD  - China-Africa Research Center of Infectious Diseases, School of Basic Medical 
      Sciences, Central South University, Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20230111
PL  - England
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
SB  - IM
OTO - NOTNLM
OT  - Probiotics
OT  - gut microbiota
OT  - inflammations
OT  - type 2 diabetes mellitus
EDAT- 2023/01/12 06:00
MHDA- 2023/01/12 06:00
CRDT- 2023/01/11 11:33
PHST- 2023/01/11 11:33 [entrez]
PHST- 2023/01/12 06:00 [pubmed]
PHST- 2023/01/12 06:00 [medline]
AID - 10.1080/13813455.2022.2163260 [doi]
PST - aheadofprint
SO  - Arch Physiol Biochem. 2023 Jan 11:1-16. doi: 10.1080/13813455.2022.2163260.